BaseLaunch: accelerating therapeutic ventures with funding of up to $500,000
It is the go-to program for developers of novel therapeutics or novel therapeutic platforms: BaseLaunch has helped launch and build ventures to the point where they can complete a Series A financing. Now, BaseLaunch is looking for highly innovative biopharma projects to support in 2021.
BaseLaunch has acquired a strong track record since launching the program in 2018: their ventures have already raised, in total, over 200 million USD in Series A rounds. The program has been ranked a top European Accelerator by Sifted.
BaseLaunch aims to help build the next generation of biotech ventures. To that end, they build a strong partnership with the scientists and entrepreneurs and provide them with the best possible conditions to build their business: Ventures benefit from up to 500’000 USD in funding and access to partners of the program, global biopharma, experts and investors. They also get support in building their team and access to lab space if needed.
Some portfolio success stories include T3 Pharma which focuses on intracellular delivery of therapeutic payloads using bacteria, exploiting bacterial tumor targeting, and since the initial funding from BaseLaunch, the company has since raised in total $42 million. Another example is Anaveon, which works towards an antibody platform re-focusing IL-2 to CTLs to fuel anti-cancer immunity. Since the funding from BaseLaunch the company has gone on to raise $37.5 million.
Andreas Katopodis, co-founder and CEO of Anaveon says that “BaseLaunch is actually so much more than just the money – their advice, expertise and network was just tremendously useful in helping us get off the ground.”
A biotech hotspot
Ventures from all over the world can apply to BaseLaunch, from very early to seed stage. Additionally, BaseLaunch helps scientists with a promising discovery and no one else to develop it. The approach is to provide individual support to each project. Hence, the schedule and program for each project is as unique as the project itself. Ventures are meant to control their entrepreneurial freedom and the extend, to which the BaseLaunch partners become involved.
While BaseLaunch is managed by Basel Area Business & Innovation and located in the Basel Area, the participants can be from anywhere in the world. The Basel Area is home to big pharma like Novartis, Roche and Actelion as well as small to medium biotech companies, world class research institutions, marquee venture capitalists and technology parks.
BaseLaunch is deeply embedded within this ecosystem, while also being connected to the global biopharma community – and utilizes both networks for the benefit of the supported ventures.
Is your therapeutic venture next? Learn more and apply today: https://baselaunch.ch/.
Please login or sign up to comment.
Commenting guidelines